The Additive Effect of Topical Dorzolamide-Timolol with Intravitreal Ranibizumab Injection in Diabetic Macular Edema

Background: Diabetic macular edema (DME) is a main reason for vision affection when occurred at any stage of diabetic retinopathy. Anti-vascular endothelial growth factor agents the gold standard treatment DME. Adjuvant may decrease and improve vision. Aim work: To assess influence topical dorzolamide–timolol with intravitreal ranibizumab injection (IVR) on anatomical functional outcomes in Patients & Methods: This prospective cohort study included thirty patients (30 eyes) having type 2 DM, aged 45-60 years, all eyes have They were divided into groups according to protocol: Group 1: 15 (15 received IVR (3 monthly Lucentis® 0.5 mg/0.05 ml) adjuvant dorzolamide-timolol (Xolamol™ eye drops twice daily). 2: only. Results: Mean BCVA variations significant both groups, it varied from 0.93 ± 0.23 logMAR baseline 0.73 0.27 (P < 0.001) group 1 0.3 0.8 0.33 = 2. Variations mean CMT 568.67 145.76 384 110.63 ˂ 513.4 114.54 387.87 119.52 2, 4th month. Conclusion: demonstrated that dorzolamide -timolol additional effects, but not statistically significant, DME over 4-month- course.